The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| JUNS | -32.82% | N/A | N/A | -89% |
| S&P | +14.39% | +76.41% | +12.02% | +15% |
Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company. Its therapeutic candidate, JOTROL is applicable to many central nervous system diseases, including Alzheimer’s disease and traumatic brain injury. The company was founded by Christer Rosén, Alexander Rosén, Claes Wahlestedt, Marshall Hayward, and Shaun P. Brothers in June 2015 and is headquartered in Jupiter, FL.
No news articles found for Jupiter Neurosciences.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $61.31M | 0.0% |
| Market Cap / Employee | $15.33M | 0.0% |
| Employees | 4 | 0.0% |
| Net Income | -$2,288.03K | -287.1% |
| EBITDA | -$2,297.05K | -365.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $723.80K | 285985.8% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | -100.0% |
| Short Term Debt | $189.60K | -91.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -555.21% | 0.0% |
| Return On Invested Capital | 46.56% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,154.45K | -2610.0% |
| Operating Free Cash Flow | -$1,154.45K | -2610.1% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Book | 4.84 | 11.02 | 45.75 | - | |
| Price to Tangible Book Value | 4.84 | 11.02 | 45.75 | - | |
| Enterprise Value to EBITDA | -240.45 | -11.50 | -14.20 | -25.85 | - |
| Total Debt | $217.76K | $205.50K | $193.34K | $189.60K | -92.09% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
